Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double blind, placebo controlled crossover study of the influence of the HCN channel blocker ivabradine in a healthy volunteer pain model - an enriched population study

Next Previous
Trial Profile

A randomised, double blind, placebo controlled crossover study of the influence of the HCN channel blocker ivabradine in a healthy volunteer pain model - an enriched population study

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ivabradine (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use

Most Recent Events

  • 01 Nov 2020 Primary endpoint has not been met. (Area of punctate mechanical hyperalgesia in capsaicin-responders)
  • 07 Oct 2015 Accrual to date is 66% according to United Kingdom Clinical Research Network.
  • 04 Sep 2015 Accrual to date is 58% according to United Kingdom Clinical Research Network.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top